1-(7-Chloroquinolin-4-yl)-2-[(1H-pyrrol-2-yl)methylene]hydrazine: a potent compound against cancer
Identifieur interne : 000618 ( Istex/Corpus ); précédent : 000617; suivant : 0006191-(7-Chloroquinolin-4-yl)-2-[(1H-pyrrol-2-yl)methylene]hydrazine: a potent compound against cancer
Auteurs : Raquel Carvalho Montenegro ; Letícia Veras Lotufo ; Manoel Odorico De Moraes ; Cláudia Do Pessoa ; Felipe Augusto Rocha Rodrigues ; Marcelle De Lima Ferreira Bispo ; Camila Cataldi De Alcantara ; Carlos Roland Kaiser ; Marcus Vinícius Nora De SouzaSource :
- Medicinal Chemistry Research [ 1054-2523 ] ; 2012-11-01.
English descriptors
- KwdEn :
Abstract
Abstract: Heteroaromatic derivatives (3a–f) have been synthesized and evaluated for their activity against four cancer cell lines. Among the studied compounds, 1-(7-Chloroquinolin-4-yl)-2-[(1H-pyrrol-2-yl)methylene]hydrazine (3e) exhibited an excellent cytotoxic activity against the referred lines, and especially on melanoma cells (MDAMB-435). In this case, compound 3e is four times more active than the standard substance Doxorubicin. Together with other results from our group, 7-chloro-4-quinolinylhydrazones derived from chloroquine could be considered a relevant finding toward the rational design of new leads for antitumor compounds.
Url:
DOI: 10.1007/s00044-011-9894-8
Links to Exploration step
ISTEX:7BEAA2020C18CECAA883F808797AED4DE52665CDLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">1-(7-Chloroquinolin-4-yl)-2-[(1H-pyrrol-2-yl)methylene]hydrazine: a potent compound against cancer</title><author><name sortKey="Montenegro, Raquel Carvalho" sort="Montenegro, Raquel Carvalho" uniqKey="Montenegro R" first="Raquel Carvalho" last="Montenegro">Raquel Carvalho Montenegro</name><affiliation><mods:affiliation>Laboratório de Genética Humana e Médica, Universidade Federal do Pará, Belém, PA, Brazil</mods:affiliation></affiliation></author><author><name sortKey="Lotufo, Leticia Veras" sort="Lotufo, Leticia Veras" uniqKey="Lotufo L" first="Letícia Veras" last="Lotufo">Letícia Veras Lotufo</name><affiliation><mods:affiliation>Laboratório de Oncologia Experimental, Universidade Federal do Ceará, Fortaleza, CE, Brazil</mods:affiliation></affiliation></author><author><name sortKey="De Moraes, Manoel Odorico" sort="De Moraes, Manoel Odorico" uniqKey="De Moraes M" first="Manoel Odorico" last="De Moraes">Manoel Odorico De Moraes</name><affiliation><mods:affiliation>Laboratório de Oncologia Experimental, Universidade Federal do Ceará, Fortaleza, CE, Brazil</mods:affiliation></affiliation></author><author><name sortKey="Pessoa, Claudia Do" sort="Pessoa, Claudia Do" uniqKey="Pessoa C" first="Cláudia Do" last="Pessoa">Cláudia Do Pessoa</name><affiliation><mods:affiliation>Laboratório de Oncologia Experimental, Universidade Federal do Ceará, Fortaleza, CE, Brazil</mods:affiliation></affiliation></author><author><name sortKey="Rodrigues, Felipe Augusto Rocha" sort="Rodrigues, Felipe Augusto Rocha" uniqKey="Rodrigues F" first="Felipe Augusto Rocha" last="Rodrigues">Felipe Augusto Rocha Rodrigues</name><affiliation><mods:affiliation>Laboratório de Oncologia Experimental, Universidade Federal do Ceará, Fortaleza, CE, Brazil</mods:affiliation></affiliation></author><author><name sortKey="De Lima Ferreira Bispo, Marcelle" sort="De Lima Ferreira Bispo, Marcelle" uniqKey="De Lima Ferreira Bispo M" first="Marcelle" last="De Lima Ferreira Bispo">Marcelle De Lima Ferreira Bispo</name><affiliation><mods:affiliation>Instituto de Tecnologia em Fármacos-Far Manguinhos, Fundação Oswaldo Cruz, Rua Sizenando Nabuco, 100, Manguinhos, 21041-250, Rio de Janeiro, RJ, Brazil</mods:affiliation></affiliation><affiliation><mods:affiliation>Instituto de Química, Departamento de Química Orgânica, Universidade Federal do Rio de Janeiro, CP 68563, 21945-970, Rio de Janeiro, RJ, Brazil</mods:affiliation></affiliation></author><author><name sortKey="De Alcantara, Camila Cataldi" sort="De Alcantara, Camila Cataldi" uniqKey="De Alcantara C" first="Camila Cataldi" last="De Alcantara">Camila Cataldi De Alcantara</name><affiliation><mods:affiliation>Instituto de Tecnologia em Fármacos-Far Manguinhos, Fundação Oswaldo Cruz, Rua Sizenando Nabuco, 100, Manguinhos, 21041-250, Rio de Janeiro, RJ, Brazil</mods:affiliation></affiliation></author><author><name sortKey="Kaiser, Carlos Roland" sort="Kaiser, Carlos Roland" uniqKey="Kaiser C" first="Carlos Roland" last="Kaiser">Carlos Roland Kaiser</name><affiliation><mods:affiliation>Instituto de Química, Departamento de Química Orgânica, Universidade Federal do Rio de Janeiro, CP 68563, 21945-970, Rio de Janeiro, RJ, Brazil</mods:affiliation></affiliation></author><author><name sortKey="De Souza, Marcus Vinicius Nora" sort="De Souza, Marcus Vinicius Nora" uniqKey="De Souza M" first="Marcus Vinícius Nora" last="De Souza">Marcus Vinícius Nora De Souza</name><affiliation><mods:affiliation>Instituto de Tecnologia em Fármacos-Far Manguinhos, Fundação Oswaldo Cruz, Rua Sizenando Nabuco, 100, Manguinhos, 21041-250, Rio de Janeiro, RJ, Brazil</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: marcos_souza@far.fiocruz.br</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7BEAA2020C18CECAA883F808797AED4DE52665CD</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1007/s00044-011-9894-8</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-NK6XBNN6-X/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000618</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000618</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">1-(7-Chloroquinolin-4-yl)-2-[(1H-pyrrol-2-yl)methylene]hydrazine: a potent compound against cancer</title><author><name sortKey="Montenegro, Raquel Carvalho" sort="Montenegro, Raquel Carvalho" uniqKey="Montenegro R" first="Raquel Carvalho" last="Montenegro">Raquel Carvalho Montenegro</name><affiliation><mods:affiliation>Laboratório de Genética Humana e Médica, Universidade Federal do Pará, Belém, PA, Brazil</mods:affiliation></affiliation></author><author><name sortKey="Lotufo, Leticia Veras" sort="Lotufo, Leticia Veras" uniqKey="Lotufo L" first="Letícia Veras" last="Lotufo">Letícia Veras Lotufo</name><affiliation><mods:affiliation>Laboratório de Oncologia Experimental, Universidade Federal do Ceará, Fortaleza, CE, Brazil</mods:affiliation></affiliation></author><author><name sortKey="De Moraes, Manoel Odorico" sort="De Moraes, Manoel Odorico" uniqKey="De Moraes M" first="Manoel Odorico" last="De Moraes">Manoel Odorico De Moraes</name><affiliation><mods:affiliation>Laboratório de Oncologia Experimental, Universidade Federal do Ceará, Fortaleza, CE, Brazil</mods:affiliation></affiliation></author><author><name sortKey="Pessoa, Claudia Do" sort="Pessoa, Claudia Do" uniqKey="Pessoa C" first="Cláudia Do" last="Pessoa">Cláudia Do Pessoa</name><affiliation><mods:affiliation>Laboratório de Oncologia Experimental, Universidade Federal do Ceará, Fortaleza, CE, Brazil</mods:affiliation></affiliation></author><author><name sortKey="Rodrigues, Felipe Augusto Rocha" sort="Rodrigues, Felipe Augusto Rocha" uniqKey="Rodrigues F" first="Felipe Augusto Rocha" last="Rodrigues">Felipe Augusto Rocha Rodrigues</name><affiliation><mods:affiliation>Laboratório de Oncologia Experimental, Universidade Federal do Ceará, Fortaleza, CE, Brazil</mods:affiliation></affiliation></author><author><name sortKey="De Lima Ferreira Bispo, Marcelle" sort="De Lima Ferreira Bispo, Marcelle" uniqKey="De Lima Ferreira Bispo M" first="Marcelle" last="De Lima Ferreira Bispo">Marcelle De Lima Ferreira Bispo</name><affiliation><mods:affiliation>Instituto de Tecnologia em Fármacos-Far Manguinhos, Fundação Oswaldo Cruz, Rua Sizenando Nabuco, 100, Manguinhos, 21041-250, Rio de Janeiro, RJ, Brazil</mods:affiliation></affiliation><affiliation><mods:affiliation>Instituto de Química, Departamento de Química Orgânica, Universidade Federal do Rio de Janeiro, CP 68563, 21945-970, Rio de Janeiro, RJ, Brazil</mods:affiliation></affiliation></author><author><name sortKey="De Alcantara, Camila Cataldi" sort="De Alcantara, Camila Cataldi" uniqKey="De Alcantara C" first="Camila Cataldi" last="De Alcantara">Camila Cataldi De Alcantara</name><affiliation><mods:affiliation>Instituto de Tecnologia em Fármacos-Far Manguinhos, Fundação Oswaldo Cruz, Rua Sizenando Nabuco, 100, Manguinhos, 21041-250, Rio de Janeiro, RJ, Brazil</mods:affiliation></affiliation></author><author><name sortKey="Kaiser, Carlos Roland" sort="Kaiser, Carlos Roland" uniqKey="Kaiser C" first="Carlos Roland" last="Kaiser">Carlos Roland Kaiser</name><affiliation><mods:affiliation>Instituto de Química, Departamento de Química Orgânica, Universidade Federal do Rio de Janeiro, CP 68563, 21945-970, Rio de Janeiro, RJ, Brazil</mods:affiliation></affiliation></author><author><name sortKey="De Souza, Marcus Vinicius Nora" sort="De Souza, Marcus Vinicius Nora" uniqKey="De Souza M" first="Marcus Vinícius Nora" last="De Souza">Marcus Vinícius Nora De Souza</name><affiliation><mods:affiliation>Instituto de Tecnologia em Fármacos-Far Manguinhos, Fundação Oswaldo Cruz, Rua Sizenando Nabuco, 100, Manguinhos, 21041-250, Rio de Janeiro, RJ, Brazil</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: marcos_souza@far.fiocruz.br</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Medicinal Chemistry Research</title><title level="j" type="abbrev">Med Chem Res</title><idno type="ISSN">1054-2523</idno><idno type="eISSN">1554-8120</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>New York</pubPlace><date type="published" when="2012-11-01">2012-11-01</date><biblScope unit="volume">21</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="3615">3615</biblScope><biblScope unit="page" to="3619">3619</biblScope></imprint><idno type="ISSN">1054-2523</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1054-2523</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antitumor activity</term><term>Cancer</term><term>Chloroquine</term><term>Drugs</term><term>Hydrazones</term><term>Quinoline</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Heteroaromatic derivatives (3a–f) have been synthesized and evaluated for their activity against four cancer cell lines. Among the studied compounds, 1-(7-Chloroquinolin-4-yl)-2-[(1H-pyrrol-2-yl)methylene]hydrazine (3e) exhibited an excellent cytotoxic activity against the referred lines, and especially on melanoma cells (MDAMB-435). In this case, compound 3e is four times more active than the standard substance Doxorubicin. Together with other results from our group, 7-chloro-4-quinolinylhydrazones derived from chloroquine could be considered a relevant finding toward the rational design of new leads for antitumor compounds.</div></front></TEI><istex><corpusName>springer-journals</corpusName><author><json:item><name>Raquel Carvalho Montenegro</name><affiliations><json:string>Laboratório de Genética Humana e Médica, Universidade Federal do Pará, Belém, PA, Brazil</json:string></affiliations></json:item><json:item><name>Letícia Veras Lotufo</name><affiliations><json:string>Laboratório de Oncologia Experimental, Universidade Federal do Ceará, Fortaleza, CE, Brazil</json:string></affiliations></json:item><json:item><name>Manoel Odorico de Moraes</name><affiliations><json:string>Laboratório de Oncologia Experimental, Universidade Federal do Ceará, Fortaleza, CE, Brazil</json:string></affiliations></json:item><json:item><name>Cláudia do Ó. Pessoa</name><affiliations><json:string>Laboratório de Oncologia Experimental, Universidade Federal do Ceará, Fortaleza, CE, Brazil</json:string></affiliations></json:item><json:item><name>Felipe Augusto Rocha Rodrigues</name><affiliations><json:string>Laboratório de Oncologia Experimental, Universidade Federal do Ceará, Fortaleza, CE, Brazil</json:string></affiliations></json:item><json:item><name>Marcelle de Lima Ferreira Bispo</name><affiliations><json:string>Instituto de Tecnologia em Fármacos-Far Manguinhos, Fundação Oswaldo Cruz, Rua Sizenando Nabuco, 100, Manguinhos, 21041-250, Rio de Janeiro, RJ, Brazil</json:string><json:string>Instituto de Química, Departamento de Química Orgânica, Universidade Federal do Rio de Janeiro, CP 68563, 21945-970, Rio de Janeiro, RJ, Brazil</json:string></affiliations></json:item><json:item><name>Camila Cataldi de Alcantara</name><affiliations><json:string>Instituto de Tecnologia em Fármacos-Far Manguinhos, Fundação Oswaldo Cruz, Rua Sizenando Nabuco, 100, Manguinhos, 21041-250, Rio de Janeiro, RJ, Brazil</json:string></affiliations></json:item><json:item><name>Carlos Roland Kaiser</name><affiliations><json:string>Instituto de Química, Departamento de Química Orgânica, Universidade Federal do Rio de Janeiro, CP 68563, 21945-970, Rio de Janeiro, RJ, Brazil</json:string></affiliations></json:item><json:item><name>Marcus Vinícius Nora de Souza</name><affiliations><json:string>Instituto de Tecnologia em Fármacos-Far Manguinhos, Fundação Oswaldo Cruz, Rua Sizenando Nabuco, 100, Manguinhos, 21041-250, Rio de Janeiro, RJ, Brazil</json:string><json:string>E-mail: marcos_souza@far.fiocruz.br</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Antitumor activity</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Cancer</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Chloroquine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Drugs</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Hydrazones</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Quinoline</value></json:item></subject><articleId><json:string>9894</json:string><json:string>s00044-011-9894-8</json:string></articleId><arkIstex>ark:/67375/VQC-NK6XBNN6-X</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>OriginalPaper</json:string></originalGenre><abstract>Abstract: Heteroaromatic derivatives (3a–f) have been synthesized and evaluated for their activity against four cancer cell lines. Among the studied compounds, 1-(7-Chloroquinolin-4-yl)-2-[(1H-pyrrol-2-yl)methylene]hydrazine (3e) exhibited an excellent cytotoxic activity against the referred lines, and especially on melanoma cells (MDAMB-435). In this case, compound 3e is four times more active than the standard substance Doxorubicin. Together with other results from our group, 7-chloro-4-quinolinylhydrazones derived from chloroquine could be considered a relevant finding toward the rational design of new leads for antitumor compounds.</abstract><qualityIndicators><score>5.228</score><pdfWordCount>2268</pdfWordCount><pdfCharCount>15609</pdfCharCount><pdfVersion>1.4</pdfVersion><pdfPageCount>5</pdfPageCount><pdfPageSize>595.276 x 790.866 pts</pdfPageSize><refBibsNative>false</refBibsNative><abstractWordCount>80</abstractWordCount><abstractCharCount>643</abstractCharCount><keywordCount>6</keywordCount></qualityIndicators><title>1-(7-Chloroquinolin-4-yl)-2-[(1H-pyrrol-2-yl)methylene]hydrazine: a potent compound against cancer</title><genre><json:string>research-article</json:string></genre><host><title>Medicinal Chemistry Research</title><language><json:string>unknown</json:string></language><publicationDate>2012</publicationDate><copyrightDate>2012</copyrightDate><issn><json:string>1054-2523</json:string></issn><eissn><json:string>1554-8120</json:string></eissn><journalId><json:string>44</json:string></journalId><volume>21</volume><issue>11</issue><pages><first>3615</first><last>3619</last></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>SC3</value></json:item><json:item><value>Cell Biology</value></json:item><json:item><value>Biochemistry, general</value></json:item><json:item><value>Pharmacology/Toxicology</value></json:item></subject></host><ark><json:string>ark:/67375/VQC-NK6XBNN6-X</json:string></ark><publicationDate>2012</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1007/s00044-011-9894-8</json:string></doi><id>7BEAA2020C18CECAA883F808797AED4DE52665CD</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-NK6XBNN6-X/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-NK6XBNN6-X/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/VQC-NK6XBNN6-X/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">1-(7-Chloroquinolin-4-yl)-2-[(1H-pyrrol-2-yl)methylene]hydrazine: a potent compound against cancer</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">Springer-Verlag</publisher><pubPlace>New York</pubPlace><availability><licence><p>Springer Science+Business Media, LLC, 2011</p></licence><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</p></availability><date>2011-08-08</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note><note>Original Research</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">1-(7-Chloroquinolin-4-yl)-2-[(1H-pyrrol-2-yl)methylene]hydrazine: a potent compound against cancer</title><author xml:id="author-0000"><persName><forename type="first">Raquel</forename><surname>Montenegro</surname></persName><affiliation>Laboratório de Genética Humana e Médica, Universidade Federal do Pará, Belém, PA, Brazil</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Letícia</forename><surname>Lotufo</surname></persName><affiliation>Laboratório de Oncologia Experimental, Universidade Federal do Ceará, Fortaleza, CE, Brazil</affiliation></author><author xml:id="author-0002"><persName><forename type="first">Manoel</forename><surname>de Moraes</surname></persName><affiliation>Laboratório de Oncologia Experimental, Universidade Federal do Ceará, Fortaleza, CE, Brazil</affiliation></author><author xml:id="author-0003"><persName><forename type="first">Cláudia</forename><surname>Pessoa</surname></persName><affiliation>Laboratório de Oncologia Experimental, Universidade Federal do Ceará, Fortaleza, CE, Brazil</affiliation></author><author xml:id="author-0004"><persName><forename type="first">Felipe</forename><surname>Rodrigues</surname></persName><affiliation>Laboratório de Oncologia Experimental, Universidade Federal do Ceará, Fortaleza, CE, Brazil</affiliation></author><author xml:id="author-0005"><persName><forename type="first">Marcelle</forename><surname>de Lima Ferreira Bispo</surname></persName><affiliation>Instituto de Tecnologia em Fármacos-Far Manguinhos, Fundação Oswaldo Cruz, Rua Sizenando Nabuco, 100, Manguinhos, 21041-250, Rio de Janeiro, RJ, Brazil</affiliation><affiliation>Instituto de Química, Departamento de Química Orgânica, Universidade Federal do Rio de Janeiro, CP 68563, 21945-970, Rio de Janeiro, RJ, Brazil</affiliation></author><author xml:id="author-0006"><persName><forename type="first">Camila</forename><surname>de Alcantara</surname></persName><affiliation>Instituto de Tecnologia em Fármacos-Far Manguinhos, Fundação Oswaldo Cruz, Rua Sizenando Nabuco, 100, Manguinhos, 21041-250, Rio de Janeiro, RJ, Brazil</affiliation></author><author xml:id="author-0007"><persName><forename type="first">Carlos</forename><surname>Kaiser</surname></persName><affiliation>Instituto de Química, Departamento de Química Orgânica, Universidade Federal do Rio de Janeiro, CP 68563, 21945-970, Rio de Janeiro, RJ, Brazil</affiliation></author><author xml:id="author-0008" corresp="yes"><persName><forename type="first">Marcus</forename><surname>de Souza</surname></persName><email>marcos_souza@far.fiocruz.br</email><affiliation>Instituto de Tecnologia em Fármacos-Far Manguinhos, Fundação Oswaldo Cruz, Rua Sizenando Nabuco, 100, Manguinhos, 21041-250, Rio de Janeiro, RJ, Brazil</affiliation></author><idno type="istex">7BEAA2020C18CECAA883F808797AED4DE52665CD</idno><idno type="ark">ark:/67375/VQC-NK6XBNN6-X</idno><idno type="DOI">10.1007/s00044-011-9894-8</idno><idno type="article-id">9894</idno><idno type="article-id">s00044-011-9894-8</idno></analytic><monogr><title level="j">Medicinal Chemistry Research</title><title level="j" type="abbrev">Med Chem Res</title><idno type="pISSN">1054-2523</idno><idno type="eISSN">1554-8120</idno><idno type="journal-ID">true</idno><idno type="issue-article-count">65</idno><idno type="volume-issue-count">12</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>New York</pubPlace><date type="published" when="2012-11-01"></date><biblScope unit="volume">21</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="3615">3615</biblScope><biblScope unit="page" to="3619">3619</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011-08-08</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: Heteroaromatic derivatives (3a–f) have been synthesized and evaluated for their activity against four cancer cell lines. Among the studied compounds, 1-(7-Chloroquinolin-4-yl)-2-[(1H-pyrrol-2-yl)methylene]hydrazine (3e) exhibited an excellent cytotoxic activity against the referred lines, and especially on melanoma cells (MDAMB-435). In this case, compound 3e is four times more active than the standard substance Doxorubicin. Together with other results from our group, 7-chloro-4-quinolinylhydrazones derived from chloroquine could be considered a relevant finding toward the rational design of new leads for antitumor compounds.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Antitumor activity</term></item><item><term>Cancer</term></item><item><term>Chloroquine</term></item><item><term>Drugs</term></item><item><term>Hydrazones</term></item><item><term>Quinoline</term></item></list></keywords></textClass><textClass><keywords scheme="Journal-Subject-Collection"><list><label>Biomedical and Life Sciences</label><item><term>SC3</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Biomedicine</head><item><term>Cell Biology</term></item><item><term>Biochemistry, general</term></item><item><term>Pharmacology/Toxicology</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2011-08-08">Created</change><change when="2012-11-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-NK6XBNN6-X/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus springer-journals not found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//Springer-Verlag//DTD A++ V2.4//EN" URI="http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd" name="istex:docType"></istex:docType><istex:document><Publisher><PublisherInfo><PublisherName>Springer-Verlag</PublisherName><PublisherLocation>New York</PublisherLocation></PublisherInfo><Journal OutputMedium="All"><JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered"><JournalID>44</JournalID><JournalPrintISSN>1054-2523</JournalPrintISSN><JournalElectronicISSN>1554-8120</JournalElectronicISSN><JournalTitle>Medicinal Chemistry Research</JournalTitle><JournalAbbreviatedTitle>Med Chem Res</JournalAbbreviatedTitle><JournalSubjectGroup><JournalSubject Type="Primary">Biomedicine</JournalSubject><JournalSubject Type="Secondary">Cell Biology</JournalSubject><JournalSubject Type="Secondary">Biochemistry, general</JournalSubject><JournalSubject Type="Secondary">Pharmacology/Toxicology</JournalSubject><SubjectCollection Code="Biomedical and Life Sciences">SC3</SubjectCollection></JournalSubjectGroup></JournalInfo><Volume OutputMedium="All"><VolumeInfo TocLevels="0" VolumeType="Regular"><VolumeIDStart>21</VolumeIDStart><VolumeIDEnd>21</VolumeIDEnd><VolumeIssueCount>12</VolumeIssueCount></VolumeInfo><Issue IssueType="Regular" OutputMedium="All"><IssueInfo IssueType="Regular" TocLevels="0"><IssueIDStart>11</IssueIDStart><IssueIDEnd>11</IssueIDEnd><IssueArticleCount>65</IssueArticleCount><IssueHistory><OnlineDate><Year>2012</Year><Month>10</Month><Day>2</Day></OnlineDate><PrintDate><Year>2012</Year><Month>10</Month><Day>1</Day></PrintDate><CoverDate><Year>2012</Year><Month>11</Month></CoverDate><PricelistYear>2012</PricelistYear></IssueHistory><IssueCopyright><CopyrightHolderName>Springer Science+Business Media New York</CopyrightHolderName><CopyrightYear>2012</CopyrightYear></IssueCopyright></IssueInfo><Article ID="s00044-011-9894-8" OutputMedium="All"><ArticleInfo ArticleType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0"><ArticleID>9894</ArticleID><ArticleDOI>10.1007/s00044-011-9894-8</ArticleDOI><ArticleSequenceNumber>33</ArticleSequenceNumber><ArticleTitle Language="En" OutputMedium="All">1-(7-Chloroquinolin-4-yl)-2-[(1H-pyrrol-2-yl)methylene]hydrazine: a potent compound against cancer</ArticleTitle><ArticleCategory>Original Research</ArticleCategory><ArticleFirstPage>3615</ArticleFirstPage><ArticleLastPage>3619</ArticleLastPage><ArticleHistory><RegistrationDate><Year>2011</Year><Month>11</Month><Day>8</Day></RegistrationDate><Received><Year>2011</Year><Month>8</Month><Day>8</Day></Received><Accepted><Year>2011</Year><Month>11</Month><Day>8</Day></Accepted><OnlineDate><Year>2011</Year><Month>11</Month><Day>27</Day></OnlineDate></ArticleHistory><ArticleCopyright><CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName><CopyrightYear>2011</CopyrightYear></ArticleCopyright><ArticleGrants Type="Regular"><MetadataGrant Grant="OpenAccess"></MetadataGrant><AbstractGrant Grant="OpenAccess"></AbstractGrant><BodyPDFGrant Grant="Restricted"></BodyPDFGrant><BodyHTMLGrant Grant="Restricted"></BodyHTMLGrant><BibliographyGrant Grant="Restricted"></BibliographyGrant><ESMGrant Grant="Restricted"></ESMGrant></ArticleGrants></ArticleInfo><ArticleHeader><AuthorGroup><Author AffiliationIDS="Aff4"><AuthorName DisplayOrder="Western"><GivenName>Raquel</GivenName><GivenName>Carvalho</GivenName><FamilyName>Montenegro</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff3"><AuthorName DisplayOrder="Western"><GivenName>Letícia</GivenName><GivenName>Veras</GivenName><FamilyName>Lotufo</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff3"><AuthorName DisplayOrder="Western"><GivenName>Manoel</GivenName><GivenName>Odorico</GivenName><Particle>de</Particle><FamilyName>Moraes</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff3"><AuthorName DisplayOrder="Western"><GivenName>Cláudia</GivenName><GivenName>do</GivenName><GivenName>Ó.</GivenName><FamilyName>Pessoa</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff3"><AuthorName DisplayOrder="Western"><GivenName>Felipe</GivenName><GivenName>Augusto</GivenName><GivenName>Rocha</GivenName><FamilyName>Rodrigues</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1 Aff2"><AuthorName DisplayOrder="Western"><GivenName>Marcelle</GivenName><Particle>de</Particle><FamilyName>Lima Ferreira Bispo</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Camila</GivenName><GivenName>Cataldi</GivenName><Particle>de</Particle><FamilyName>Alcantara</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff2"><AuthorName DisplayOrder="Western"><GivenName>Carlos</GivenName><GivenName>Roland</GivenName><FamilyName>Kaiser</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1" CorrespondingAffiliationID="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Marcus</GivenName><GivenName>Vinícius</GivenName><GivenName>Nora</GivenName><Particle>de</Particle><FamilyName>Souza</FamilyName></AuthorName><Contact><Phone>+552139772404</Phone><Fax>+552125602518</Fax><Email>marcos_souza@far.fiocruz.br</Email></Contact></Author><Affiliation ID="Aff1"><OrgDivision>Instituto de Tecnologia em Fármacos-Far Manguinhos</OrgDivision><OrgName>Fundação Oswaldo Cruz</OrgName><OrgAddress><Street>Rua Sizenando Nabuco, 100, Manguinhos</Street><City>Rio de Janeiro</City><State>RJ</State><Postcode>21041-250</Postcode><Country Code="BR">Brazil</Country></OrgAddress></Affiliation><Affiliation ID="Aff2"><OrgDivision>Instituto de Química, Departamento de Química Orgânica</OrgDivision><OrgName>Universidade Federal do Rio de Janeiro</OrgName><OrgAddress><Street>CP 68563</Street><City>Rio de Janeiro</City><State>RJ</State><Postcode>21945-970</Postcode><Country Code="BR">Brazil</Country></OrgAddress></Affiliation><Affiliation ID="Aff3"><OrgDivision>Laboratório de Oncologia Experimental</OrgDivision><OrgName>Universidade Federal do Ceará</OrgName><OrgAddress><City>Fortaleza</City><State>CE</State><Country Code="BR">Brazil</Country></OrgAddress></Affiliation><Affiliation ID="Aff4"><OrgDivision>Laboratório de Genética Humana e Médica</OrgDivision><OrgName>Universidade Federal do Pará</OrgName><OrgAddress><City>Belém</City><State>PA</State><Country Code="BR">Brazil</Country></OrgAddress></Affiliation></AuthorGroup><Abstract ID="Abs1" Language="En" OutputMedium="All"><Heading>Abstract</Heading><Para>Heteroaromatic derivatives (<Emphasis Type="Bold">3a</Emphasis>–<Emphasis Type="Bold">f</Emphasis>) have been synthesized and evaluated for their activity against four cancer cell lines. Among the studied compounds, 1-(7-Chloroquinolin-4-yl)-2-[(1H-pyrrol-2-yl)methylene]hydrazine (<Emphasis Type="Bold">3e</Emphasis>) exhibited an excellent cytotoxic activity against the referred lines, and especially on melanoma cells (MDAMB-435). In this case, compound <Emphasis Type="Bold">3e</Emphasis> is four times more active than the standard substance Doxorubicin. Together with other results from our group, 7-chloro-4-quinolinylhydrazones derived from chloroquine could be considered a relevant finding toward the rational design of new leads for antitumor compounds.</Para></Abstract><KeywordGroup Language="En" OutputMedium="All"><Heading>Keywords</Heading><Keyword>Antitumor activity</Keyword><Keyword>Cancer</Keyword><Keyword>Chloroquine</Keyword><Keyword>Drugs</Keyword><Keyword>Hydrazones</Keyword><Keyword>Quinoline</Keyword></KeywordGroup></ArticleHeader><NoBody></NoBody></Article></Issue></Volume></Journal></Publisher></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>1-(7-Chloroquinolin-4-yl)-2-[(1H-pyrrol-2-yl)methylene]hydrazine: a potent compound against cancer</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>1-(7-Chloroquinolin-4-yl)-2-[(1H-pyrrol-2-yl)methylene]hydrazine: a potent compound against cancer</title></titleInfo><name type="personal"><namePart type="given">Raquel</namePart><namePart type="given">Carvalho</namePart><namePart type="family">Montenegro</namePart><affiliation>Laboratório de Genética Humana e Médica, Universidade Federal do Pará, Belém, PA, Brazil</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Letícia</namePart><namePart type="given">Veras</namePart><namePart type="family">Lotufo</namePart><affiliation>Laboratório de Oncologia Experimental, Universidade Federal do Ceará, Fortaleza, CE, Brazil</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Manoel</namePart><namePart type="given">Odorico</namePart><namePart type="family">de Moraes</namePart><affiliation>Laboratório de Oncologia Experimental, Universidade Federal do Ceará, Fortaleza, CE, Brazil</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Cláudia</namePart><namePart type="given">do</namePart><namePart type="given">Ó.</namePart><namePart type="family">Pessoa</namePart><affiliation>Laboratório de Oncologia Experimental, Universidade Federal do Ceará, Fortaleza, CE, Brazil</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Felipe</namePart><namePart type="given">Augusto</namePart><namePart type="given">Rocha</namePart><namePart type="family">Rodrigues</namePart><affiliation>Laboratório de Oncologia Experimental, Universidade Federal do Ceará, Fortaleza, CE, Brazil</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Marcelle</namePart><namePart type="family">de Lima Ferreira Bispo</namePart><affiliation>Instituto de Tecnologia em Fármacos-Far Manguinhos, Fundação Oswaldo Cruz, Rua Sizenando Nabuco, 100, Manguinhos, 21041-250, Rio de Janeiro, RJ, Brazil</affiliation><affiliation>Instituto de Química, Departamento de Química Orgânica, Universidade Federal do Rio de Janeiro, CP 68563, 21945-970, Rio de Janeiro, RJ, Brazil</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Camila</namePart><namePart type="given">Cataldi</namePart><namePart type="family">de Alcantara</namePart><affiliation>Instituto de Tecnologia em Fármacos-Far Manguinhos, Fundação Oswaldo Cruz, Rua Sizenando Nabuco, 100, Manguinhos, 21041-250, Rio de Janeiro, RJ, Brazil</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Carlos</namePart><namePart type="given">Roland</namePart><namePart type="family">Kaiser</namePart><affiliation>Instituto de Química, Departamento de Química Orgânica, Universidade Federal do Rio de Janeiro, CP 68563, 21945-970, Rio de Janeiro, RJ, Brazil</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal" displayLabel="corresp"><namePart type="given">Marcus</namePart><namePart type="given">Vinícius</namePart><namePart type="given">Nora</namePart><namePart type="family">de Souza</namePart><affiliation>Instituto de Tecnologia em Fármacos-Far Manguinhos, Fundação Oswaldo Cruz, Rua Sizenando Nabuco, 100, Manguinhos, 21041-250, Rio de Janeiro, RJ, Brazil</affiliation><affiliation>E-mail: marcos_souza@far.fiocruz.br</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="OriginalPaper" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>Springer-Verlag</publisher><place><placeTerm type="text">New York</placeTerm></place><dateCreated encoding="w3cdtf">2011-08-08</dateCreated><dateIssued encoding="w3cdtf">2012-11-01</dateIssued><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><abstract lang="en">Abstract: Heteroaromatic derivatives (3a–f) have been synthesized and evaluated for their activity against four cancer cell lines. Among the studied compounds, 1-(7-Chloroquinolin-4-yl)-2-[(1H-pyrrol-2-yl)methylene]hydrazine (3e) exhibited an excellent cytotoxic activity against the referred lines, and especially on melanoma cells (MDAMB-435). In this case, compound 3e is four times more active than the standard substance Doxorubicin. Together with other results from our group, 7-chloro-4-quinolinylhydrazones derived from chloroquine could be considered a relevant finding toward the rational design of new leads for antitumor compounds.</abstract><note>Original Research</note><subject lang="en"><genre>Keywords</genre><topic>Antitumor activity</topic><topic>Cancer</topic><topic>Chloroquine</topic><topic>Drugs</topic><topic>Hydrazones</topic><topic>Quinoline</topic></subject><relatedItem type="host"><titleInfo><title>Medicinal Chemistry Research</title></titleInfo><titleInfo type="abbreviated"><title>Med Chem Res</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>Springer</publisher><dateIssued encoding="w3cdtf">2012-10-02</dateIssued><copyrightDate encoding="w3cdtf">2012</copyrightDate></originInfo><subject><genre>Journal-Subject-Collection</genre><topic authority="SpringerSubjectCodes" authorityURI="Biomedical and Life Sciences">SC3</topic></subject><subject><genre>Biomedicine</genre><topic>Cell Biology</topic><topic>Biochemistry, general</topic><topic>Pharmacology/Toxicology</topic></subject><identifier type="ISSN">1054-2523</identifier><identifier type="eISSN">1554-8120</identifier><identifier type="JournalID">44</identifier><identifier type="IssueArticleCount">65</identifier><identifier type="VolumeIssueCount">12</identifier><part><date>2012</date><detail type="volume"><number>21</number><caption>vol.</caption></detail><detail type="issue"><number>11</number><caption>no.</caption></detail><extent unit="pages"><start>3615</start><end>3619</end></extent></part><recordInfo><recordOrigin>Springer Science+Business Media New York, 2012</recordOrigin></recordInfo></relatedItem><identifier type="istex">7BEAA2020C18CECAA883F808797AED4DE52665CD</identifier><identifier type="ark">ark:/67375/VQC-NK6XBNN6-X</identifier><identifier type="DOI">10.1007/s00044-011-9894-8</identifier><identifier type="ArticleID">9894</identifier><identifier type="ArticleID">s00044-011-9894-8</identifier><accessCondition type="use and reproduction" contentType="copyright">Springer Science+Business Media, LLC, 2011</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</recordContentSource><recordOrigin>Springer Science+Business Media, LLC, 2011</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-NK6XBNN6-X/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000618 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000618 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:7BEAA2020C18CECAA883F808797AED4DE52665CD
|texte= 1-(7-Chloroquinolin-4-yl)-2-[(1H-pyrrol-2-yl)methylene]hydrazine: a potent compound against cancer
}}
| This area was generated with Dilib version V0.6.33. |  |